Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol
Authors: Jason L. Vassy, J. Michael Gaziano, Robert C. Green, Ryan E. Ferguson, Sanjay Advani, Stephen J. Miller, Sojeong Chun, Anthony K. Hage, Soo-Ji Seo, Nilla Majahalme, Lauren MacMullen, Andrew J. Zimolzak, Charles A. Brunette
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Nonadherence to statin guidelines is common. The solute carrier organic anion transporter family member 1B1 (<i>SLCO1B1</i>) genotype is associated with simvastatin myopathy risk and is proposed for clinical implementation. The unintended harms of using pharmacogenetic information to guide pharmacotherapy remain a concern for some stakeholders. <h3>Objective</h3> To determine the impact of delivering<i>SLCO1B1</i>pharmacogenetic results to physicians on the effectiveness of atherosclerotic cardiovascular disease (ASCVD) prevention (measured by low-density lipoprotein cholesterol [LDL-C] levels) and concordance with prescribing guidelines for statin safety and effectiveness. <h3>Design, Setting, and Participants</h3> This randomized clinical trial was performed from December 2015 to July 2019 at 8 primary care practices in the Veterans Affairs Boston Healthcare System. Participants included statin-naive patients with elevated ASCVD risk. Data analysis was performed from October 2019 to September 2020. <h3>Interventions</h3> <i>SLCO1B1</i>genotyping and results reporting to primary care physicians at baseline (intervention group) vs after 1 year (control group). <h3>Main Outcomes and Measures</h3> The primary outcome was the 1-year change in LDL-C level. The secondary outcomes were 1-year concordance with American College of Cardiology–American Heart Association and Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for statin therapy and statin-associated muscle symptoms (SAMS). <h3>Results</h3> Among 408 patients (mean [SD] age, 64.1 [7.8] years; 25 women [6.1%]), 193 were randomized to the intervention group and 215 were randomized to the control group. Overall, 120 participants (29%) had a<i>SLCO1B1</i>genotype indicating increased simvastatin myopathy risk. Physicians offered statin therapy to 65 participants (33.7%) in the intervention group and 69 participants (32.1%) in the control group. Compared with patients whose physicians did not know their<i>SLCO1B1</i>results at baseline, patients whose physicians received the results had noninferior reductions in LDL-C at 12 months (mean [SE] change in LDL-C, −1.1 [1.2] mg/dL in the intervention group and −2.2 [1.3] mg/dL in the control group; difference, −1.1 mg/dL; 90% CI, −4.1 to 1.8 mg/dL;<i>P</i> &lt; .001 for noninferiority margin of 10 mg/dL). The proportion of patients with American College of Cardiology–American Heart Association guideline-concordant statin prescriptions in the intervention group was noninferior to that in the control group (12 patients [6.2%] vs 14 patients [6.5%]; difference, −0.003; 90% CI, −0.038 to 0.032;<i>P</i> &lt; .001 for noninferiority margin of 15%). All patients in both groups were concordant with CPIC guidelines for safe statin prescribing. Physicians documented 2 and 3 cases of SAMS in the intervention and control groups, respectively, none of which was associated with a CPIC guideline–discordant prescription. Among patients with a decreased or poor<i>SLCO1B1</i>transporter function genotype, simvastatin was prescribed to 1 patient in the control group but none in the intervention group. <h3>Conclusions and Relevance</h3> Clinical testing and reporting of<i>SLCO1B1</i>results for statin myopathy risk did not result in poorer ASCVD prevention in a routine primary care setting and may have been associated with physicians avoiding simvastatin prescriptions for patients at genetic risk for SAMS. Such an absence of harm should reassure stakeholders contemplating the clinical use of available pharmacogenetic results. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02871934